About Rules-Based Medicine
Rules-Based Medicine is a company based in Austin (United States) founded in 2002 was acquired by Myriad Genetics in April 2011. Rules-Based Medicine has raised $25 million across 1 funding round from investors including Myriad Genetics, The Stephens Group and Cross Creek. Rules-Based Medicine operates in a competitive market with competitors including Anabios, Clyde Biosciences, Metrion Biosciences, Quiver Bioscience and Zen-Bio, among others.
- Headquarter Austin, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$25 M (USD)
in 1 rounds
-
Latest Funding Round
$25 M (USD), Series A
Oct 15, 2007
-
Investors
Myriad Genetics
& 2 more
-
Employee Count
Not available
-
Acquired by
Myriad Genetics
(Apr 27, 2011)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Rules-Based Medicine
Rules-Based Medicine has successfully raised a total of $25M through 1 strategic funding round. The most recent funding activity was a Series A round of $25 million completed in October 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Rules-Based Medicine
Rules-Based Medicine has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Myriad Genetics, The Stephens Group and Cross Creek.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Sector-agnostic investments in late-stage startups are made by Cross Creek.
|
Locked | Locked | Locked | |
|
Molecular diagnostics and personalized medicine for cancer are developed.
|
Locked | Locked | Locked |
Investor details for Rules-Based Medicine
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Rules-Based Medicine
Investment portfolio details for Rules-Based Medicine
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Rules-Based Medicine
Detailed financials for Rules-Based Medicine
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Rules-Based Medicine Comparisons
Peer comparison for Rules-Based Medicine
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Rules-Based Medicine
Rules-Based Medicine operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Anabios, Clyde Biosciences, Metrion Biosciences, Quiver Bioscience and Zen-Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Ex-vivo human tissue studies are performed for preclinical drug discovery.
|
|
| Locked | Locked | Locked |
Cardiac safety testing is conducted using iPS-derived heart cells.
|
|
| Locked | Locked | Locked |
Ion channel screening and cardiac safety profiling services are provided.
|
|
| Locked | Locked | Locked |
Developer of transformational medicines for neurological disorders
|
|
| Locked | Locked | Locked |
Cell-based solutions are provided to accelerate therapy discovery and development.
|
Detailed competitors of Rules-Based Medicine
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Rules-Based Medicine
Complete news archive for Rules-Based Medicine
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rules-Based Medicine
Rules-Based Medicine was founded in 2002 and raised its 1st funding round 5 years after it was founded.
Rules-Based Medicine is headquartered in Austin, United States. It is registered at Austin, Texas, United States.
Rules-Based Medicine is a funded company, having raised a total of $25M across 1 funding round to date.
Rules-Based Medicine was founded in 2002 in Austin, United States, focusing on biotechnology diagnostics. Multiplexed biomarker assays are created using the Multi-Analyte Profiling platform for protein analysis. The company was acquired by Myriad Genetics in April 2011 for 80 million in cash and now functions as a subsidiary known as Myriad RBM, supporting biomarker research and development in the diagnostics sector.
Rules-Based Medicine's top competitors include Metrion Biosciences, Quiver Bioscience and Anabios.
Rules-Based Medicine has 3 investors. Key investors include Myriad Genetics, The Stephens Group, and Cross Creek.